5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation.
Cho YH, Ro EJ, Yoon JS, Mizutani T, Kang DW, Park JC, Il Kim T, Clevers H, Choi KY. · 2020
Read 5-FU promotes stemness of colorectal cancer via p53-mediated WNT/β-catenin pathway activation. by Cho YH, Ro EJ, Yoon JS, Mizutani T, Kang DW, Park JC, Il Kim T, Clevers H, Choi KY. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7578039.txt.
Description
Cho and co-authors show that 5-FU can promote stemness in colorectal cancer through p53. The drug 5-FU is first-line care for this cancer. Tumors often shrink at first, then return after treatment.
The team found p53 raises WNT3 gene activity. That switch turns on the WNT and beta-catenin pathway. Models included mice, patient tumor organoids and patient cells. Through this route, 5-FU enriched cancer stem cells. Those cells in leftover tumors drive recurrence. A WNT inhibitor paired with 5-FU suppressed stem cells. The pairing also cut tumor regrowth after treatment stopped. The findings suggest a new combination plan for colorectal cancer care.
Catalog record
| CREATOR | Cho YH, Ro EJ, Yoon JS, Mizutani T, Kang DW, Park JC, Il Kim T, Clevers H, Choi KY. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |